Current Cardiology Reviews最新文献_第2页

The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis.

IF 2.4

Current Cardiology Reviews Pub Date : 2025-02-13 DOI: 10.2174/011573403X345749250122092324

Rubela Ray, Arhum Mahmood, Raheel Chaudhry, Mohd Diya Masmoum, Muhammad Talha, Fahad I Siddiqui, Imdad Ullah

{"title":"The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis.","authors":"Rubela Ray, Arhum Mahmood, Raheel Chaudhry, Mohd Diya Masmoum, Muhammad Talha, Fahad I Siddiqui, Imdad Ullah","doi":"10.2174/011573403X345749250122092324","DOIUrl":"https://doi.org/10.2174/011573403X345749250122092324","url":null,"abstract":"Introduction: Reducing the risk of atherosclerotic cardiovascular disease is the aim of lipid-lowering therapy (ASCVD). It is commonly acknowledged that low-density lipoprotein (LDL) is a major cause of ASCVD. Several online databases and search engines, such as Pub- Med and the Cochrane Library, were used to conduct a thorough search.Method: This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events. The RevMan 5.4 software was used to conduct the meta-analysis. This analysis included nine RCTs in total.Results: Meta-analysis of the included studies showed that the levels of total cholesterol, LDL, and triglycerides were reduced after the use of PCSK9 inhibitors, and HDL levels were increased, which is good cholesterol. Most adverse cardiac events (MACE) were reduced after the use of PCSK9 inhibitors.Conclusion: In conclusion, ezetimibe, a PCSK9 inhibitor added to statin therapy, further reduces MACE risk without affecting all-cause mortality, even though statins already significantly reduce major adverse cardiovascular events (MACE) and mortality.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Slowing Thoracic Aortic Aneurysm Growth with Statins: A Meta-Analysis.

IF 2.4

Current Cardiology Reviews Pub Date : 2025-02-13 DOI: 10.2174/011573403X343512250127075044

Amie Marie Kolimas, Gargya Malla, Abhimanyu Chadha, Enkhtsogt Sainbayar, Joshua Sethi, Ziad Hindosh, Priyanka Hadvani, Hoang Nhat Pham, Juan Sordia

{"title":"Slowing Thoracic Aortic Aneurysm Growth with Statins: A Meta-Analysis.","authors":"Amie Marie Kolimas, Gargya Malla, Abhimanyu Chadha, Enkhtsogt Sainbayar, Joshua Sethi, Ziad Hindosh, Priyanka Hadvani, Hoang Nhat Pham, Juan Sordia","doi":"10.2174/011573403X343512250127075044","DOIUrl":"https://doi.org/10.2174/011573403X343512250127075044","url":null,"abstract":"Background: Thoracic aortic aneurysms (TAAs) are worrisome for their propensity to dissect. Previous studies have demonstrated the potential benefits of statin use, particularly with slowing aortic aneurysm growth. The aim of this meta-analysis was to consolidate existing research to ascertain if statins effectively reduce TAA growth.Methods: Multiple databases were searched to identify studies assessing TAA growth in patients on statins (cases) and those not on statins (controls). The primary outcome was TAA (ascending/ aortic arch) growth rate per year. Standard mean difference (SMD) and 95% confidence intervals (95% CI) were estimated with a random-effects model using the inverse-variance technique. We assigned I2>50% as an indicator of statistical heterogeneity. P-value <0.05 was considered significant. Data analysis was performed using SPSS v.25.0.Results: Four studies comprising 757 cases (male 64%, mean age 65±14 years) and 1,696 controls (male 62%, mean age 61±18 years) were included. The baseline diameters of TAA for cases and controls were 40.35±8.75mm and 42.39±12.60mm, respectively. Pooled results suggested statins to be associated with slower growth of TAAs with pooled SMD -0.70 mm/year [95% CI (-1.23 - -0.16); p=0.01]. Heterogeneity statistics among 4 studies was 95%.Conclusion: This pooled meta-analysis showed statins as associated with slower growth of TAAs. However, given the heterogeneity of the included studies in this meta-analysis, results should be interpreted with caution.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-Bacterial Thrombotic Endocarditis in Lung Cancer: A Systematic Review.

IF 2.4

Current Cardiology Reviews Pub Date : 2025-02-11 DOI: 10.2174/011573403X343187250117062341

Maikel Kamel, Fahad Hussain, Christian Leung, Awais Paracha, Pranav Sathe, Ajay Jassal, Mahalia Huba, Umar Durrani, Nadim Ammari, Robert S Copeland-Halperin, Nagashree Seetharamu

{"title":"Non-Bacterial Thrombotic Endocarditis in Lung Cancer: A Systematic Review.","authors":"Maikel Kamel, Fahad Hussain, Christian Leung, Awais Paracha, Pranav Sathe, Ajay Jassal, Mahalia Huba, Umar Durrani, Nadim Ammari, Robert S Copeland-Halperin, Nagashree Seetharamu","doi":"10.2174/011573403X343187250117062341","DOIUrl":"https://doi.org/10.2174/011573403X343187250117062341","url":null,"abstract":"Introduction: Nonbacterial Thrombotic Endocarditis (NBTE) is a rare condition characterized by aseptic vegetations of the heart valves, predisposing to valvular dysfunction and end-organ infarction. Lung Cancer (LC) is amongst the most common malignancies associated with NBTE.Methods: PubMed/MEDLINE was searched from database inception until January 2024, pairing \"Non-Bacterial Thrombotic Endocarditis (NBTE) and related terms with \"Lung Cancer\"( LC). Reports were included if patients had both NBTE and lung cancer. The risk of bias was assessed using Mixed Methods Analysis Testing (MMAT).Results: 32 patients with an average age of 59y +/- 11.6 were included from 31 peer-reviewed publications, with significant findings as below: • The majority (47%) of patients were admitted with stroke. • The most commonly affected valve was aortic (51%), followed by mitral (43%), and tricuspid (5%). • At diagnosis of NBTE, 86% of patients had stage IV cancer. • Multi-organ infarct was common (61%), with the brain most often affected (40%). • Treatment of NBTE included antibiotics (86%), anticoagulation (50%), and cardiac surgery (6%). • Treatment of LC included traditional chemotherapy (30.7%), radiation (16%), tyrosine kinase inhibitors (11.5%), lobectomy (6%), and immunotherapy (3.8%). • Overall mortality rate was 77%. • Mortality rate was 38% in patients treated with chemotherapy and 91% in patients who did not receive chemotherapy. • Mortality rate stratified by anticoagulant: unfractionated heparin (85.7%), DOAC (75%), and LMWH (20%).Conclusion: High clinical suspicion for NBTE in patients presenting with LC and thromboembolic phenomena can lead to changes in treatment and improved clinical outcomes.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Incidence of Heart Failure in Children with Congenital Heart Disease: A Prospective Cohort Study.

IF 2.4

Current Cardiology Reviews Pub Date : 2025-02-11 DOI: 10.2174/011573403X345783250128052038

Yasamin Moeinipour, Aliasghar Moeinipour, Behzad Alizadeh, Rasoul Raesi, Mohammadreza Naghibi

{"title":"The Incidence of Heart Failure in Children with Congenital Heart Disease: A Prospective Cohort Study.","authors":"Yasamin Moeinipour, Aliasghar Moeinipour, Behzad Alizadeh, Rasoul Raesi, Mohammadreza Naghibi","doi":"10.2174/011573403X345783250128052038","DOIUrl":"https://doi.org/10.2174/011573403X345783250128052038","url":null,"abstract":"Background: Pediatric heart failure (HF) poses diagnostic challenges, especially in emergency settings, where misdiagnoses are common.Aim: This study aimed to investigate the causes of HF in children with congenital heart disease (CHD) and provide insights into age-related disparities and clinical classifications.Methods: A prospective observational cohort study was conducted on 402 pediatric patients with CHD during the years 2019-2020. Ultimately, 45 pediatric patients diagnosed with HF by two pediatric cardiologists based on clinical symptoms and radiographic changes were included in the study. Information from the patients' files, including epidemiological findings, clinical examinations, paraclinical findings, and interventions performed, was recorded. Etiological factors and clinical classifications were analyzed using statistical tests.Results: Among 402 pediatric patients with CHD, 45 (11.19%) were diagnosed with HF, with a median age of 7.5 months. The predominant etiological factors included ventricular septal defect (VSD), atrial septal defect (ASD), and cardiomyopathy. CHD was prevalent in 86.66% of the cases. Clinical classifications revealed age-related differences, emphasizing the heterogeneity of pediatric HF presentations.Conclusion: Considering that 86.7% of the patients with HF in our study had CHD, more investigations into the causes and mechanisms of this issue are necessary, which will be possible with genetic studies. A significant difference was observed between Class II and Class IV, with Class II patients being older and heavier, and having a lower heart rate compared to those in Class IV. This aligns with the classifications, where Class II indicates mild symptoms during ordinary activity, while Class IV signifies severe symptoms at rest.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Red Blood Cells in Cholesterol Accumulation and Atherosclerotic Plaque Instability: A Perspective on Atherosclerosis.

IF 2.4

Current Cardiology Reviews Pub Date : 2025-02-11 DOI: 10.2174/011573403X358572250128104335

Reza Mohebbati, Mohammad Amin Momeni Moghaddam

{"title":"The Role of Red Blood Cells in Cholesterol Accumulation and Atherosclerotic Plaque Instability: A Perspective on Atherosclerosis.","authors":"Reza Mohebbati, Mohammad Amin Momeni Moghaddam","doi":"10.2174/011573403X358572250128104335","DOIUrl":"https://doi.org/10.2174/011573403X358572250128104335","url":null,"abstract":"Atherosclerosis stands as the primary cause of CVD, characterized by the accumulation of cholesterol deposits within macrophages in medium and large arteries. This deposition promotes the proliferation of specific cell types within the arterial wall, gradually narrowing the vessel lumen and impeding blood flow. Intra-plaque hemorrhages are recognized as critical events in atherosclerotic plaques, leading to the deposition of red blood cells (RBCs) and the release of hemoglobin (Hb). Approximately 40% of high-risk plaques exhibit intra-plaque hemorrhage. Recent studies have demonstrated that intra-plaque hemorrhage is closely linked to plaque progression and increased vulnerability, establishing it as a critical factor in the development of acute clinical symptoms associated with atherosclerosis. The presence of RBC membranes within atherosclerotic plaques contributes significantly to lipid accumulation, indicating a pivotal role in plaque instability. Upon RBC degradation, cholesterol from both the membrane and its interior can profoundly impact atherosclerotic plaque development. Considering that red blood cells (RBCs) can contribute to the excretion of cholesterol through the hepatobiliary system alongside HDL, and given that elevated cholesterol levels are a risk factor for the development and progression of atherosclerotic plaques, RBCs may play a protective role in cardiovascular health. However, when bleeding occurs within a plaque, RBCs that are trapped in the plaque environment, an environment rich in oxidant compounds, can rupture. The cholesterol released from these ruptured RBCs can significantly promote inflammatory reactions. This study aims to explore the inconsistent role of RBCs and their cholesterol content in the progression of atherosclerotic plaques.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Physical Exercise and the Use of Doxorubicin on Cardiac Function in Rodents: A Systematic Review and Meta-Analysis.

IF 2.4

Current Cardiology Reviews Pub Date : 2025-02-10 DOI: 10.2174/011573403X328856241219114652

Bruno Gama Linhares, Diego Gama Linhares, Rodrigo Gomes de Souza Vale

{"title":"Effects of Physical Exercise and the Use of Doxorubicin on Cardiac Function in Rodents: A Systematic Review and Meta-Analysis.","authors":"Bruno Gama Linhares, Diego Gama Linhares, Rodrigo Gomes de Souza Vale","doi":"10.2174/011573403X328856241219114652","DOIUrl":"https://doi.org/10.2174/011573403X328856241219114652","url":null,"abstract":"Background: Anthracycline-based chemotherapy, such as Doxorubicin (DOX), often induces cardiotoxicity in cancer patients, which compromises their health and quality of life.Objective: This study aimed to verify the effects of exercise concomitant with prolonged administration of DOX on improving cardiotoxicity.Methods: A systematic literature search in MedLine, PubMed, Web of Science, and Scopus databases was performed from inception until November 2023, strictly following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. Preclinical randomized controlled trials related to exercise, cardiotoxicity, and DOX were included.Results: Eight studies were included in the systematic review and 7 were selected for metaanalysis. By evaluating the Fractional Shortening (FS), it was possible to verify that exercise as complementary therapy provided a cardioprotective effect when compared to DOX combined with sedentary behavior (heterogeneity: I² = 53%; tau² = 0.19; p = 0.03; overall effect: z = 2.69; p < 0.01). However, no additional benefits were observed for the Left Ventricular Ejection Fraction (LVEF) (heterogeneity: I² = 82%; tau² = 1.43; p < 0.01; overall effect: z = 1.42; p = 0.15).Conclusion: The included studies demonstrated exercise to have a cardioprotective effect on rodents, mainly on FS. However, there is a lack of high-level evidence to guide exercise prescription in clinical practice to improve cardiotoxicity associated with DOX administration.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of Left Ventricular Shape Index and Eccentricity Index as Promising Parameters for Detection of Left Ventricular Remodeling in Cardiovascular Events.

IF 2.4

Current Cardiology Reviews Pub Date : 2025-02-07 DOI: 10.2174/011573403X357558250122062037

Fatemeh Jalali-Zefrei, Zobin Souri, Faranak Izadi Benam, Paradise Fatehi Shalamzari, Pouya Yektaee, Seyedeh Zohreh Mohagheghi, Aliasghar Tabatabaei Mohammadi, Soghra Farzipour

{"title":"Assessment of Left Ventricular Shape Index and Eccentricity Index as Promising Parameters for Detection of Left Ventricular Remodeling in Cardiovascular Events.","authors":"Fatemeh Jalali-Zefrei, Zobin Souri, Faranak Izadi Benam, Paradise Fatehi Shalamzari, Pouya Yektaee, Seyedeh Zohreh Mohagheghi, Aliasghar Tabatabaei Mohammadi, Soghra Farzipour","doi":"10.2174/011573403X357558250122062037","DOIUrl":"https://doi.org/10.2174/011573403X357558250122062037","url":null,"abstract":"Left ventricular remodeling (LVR) refers to the changes in the size, shape, and function of the left ventricle, influenced by mechanical, neurohormonal, and genetic factors. These changes are directly linked to an increased risk of major adverse cardiac events (MACEs). Various parameters are used to assess cardiac geometry across different imaging modalities, with echocardiography being the most commonly employed technique for measuring left ventricular (LV) geometry. However, many echocardiographic evaluations of geometric changes primarily rely on two-dimensional (2D) methods, which overlook the true three-dimensional (3D) characteristics of the LV. While cardiac magnetic resonance (CMR) imaging is considered the gold standard for assessing LV volume, it has limitations, including accessibility issues, challenges in patients with cardiac devices, and longer examination times compared to standard echocardiography. In nuclear medicine, LV geometry can be analyzed using the shape index (SI) and eccentricity index (EI), which measure the sphericity and elongation of the left ventricle. Myocardial perfusion imaging (MPI) using SPECT or PET is inherently a 3D technique, making it particularly effective for accurately and consistently assessing LV size and shape parameters. In this context, LV metrics such as EI and SI can significantly enhance the range of quantitative assessments available through nuclear cardiology techniques, with particular value in identifying early LV remodeling in specific patient groups. This article explores the diagnostic significance of left ventricular geometric indices through various diagnostic methods, highlighting the important role of nuclear cardiology.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leptin Resistance and Cardiometabolic Disorders: Bridging Molecular Pathways, Genetic Variants, and Therapeutic Innovation. 瘦素抵抗与心脏代谢疾病：连接分子途径、遗传变异和治疗创新。

IF 2.4

Current Cardiology Reviews Pub Date : 2025-02-07 DOI: 10.2174/011573403X356019250118170444

Prashanjit Roy, Rishi Kant, Amandeep Kaur, Hardik Kumar, Ranjeet Kumar

{"title":"Leptin Resistance and Cardiometabolic Disorders: Bridging Molecular Pathways, Genetic Variants, and Therapeutic Innovation.","authors":"Prashanjit Roy, Rishi Kant, Amandeep Kaur, Hardik Kumar, Ranjeet Kumar","doi":"10.2174/011573403X356019250118170444","DOIUrl":"https://doi.org/10.2174/011573403X356019250118170444","url":null,"abstract":"Leptin, a hormone produced by fat cells, is crucial for regulating energy equilibrium, managing body mass, and influencing metabolic and cardiovascular well-being. Leptin decreases appetite, boosts energy usage, and has a significant impact on glucose metabolism by primarily activating the JAK2/STAT3 signaling pathway in the hypothalamus. Obesity leads to the development of leptin resistance, which is marked by high levels of leptin in the bloodstream and a decreased responsiveness to its signals. This leads to increased food consumption, weight gain, and metabolic issues, such as type 2 diabetes (T2DM) and cardiovascular disease (CVD). This study explores the many roles of leptin in metabolic regulation, with a specific emphasis on its interaction with insulin and its impact on peripheral organs like the pancreas, liver, and muscles. Leptin resistance worsens chronic inflammation, oxidative stress, endothelial dysfunction, and insulin resistance, all of which are strongly linked to the development of cardiovascular disease (CVD). Moreover, there is a correlation between genetic variations in the leptin receptor (LEPR) gene and a higher susceptibility to stroke and other cardiovascular issues. Therapeutic interventions, such as leptin replacement therapy, have demonstrated potential in the treatment of congenital leptin insufficiency and lipodystrophy while also enhancing glycaemic control, lipid profiles, and neuroendocrine function. Recent studies have indicated that manipulating leptin levels or enhancing its responsiveness by specific treatments, such as chemical chaperones and inhibitors of negative regulators like SOCS3 and PTP1B, might potentially restore the efficacy of leptin.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence in the Heart of Medicine: Transforming Arrhythmia Care with Intelligent Systems.

IF 2.4

Current Cardiology Reviews Pub Date : 2025-02-03 DOI: 10.2174/011573403X334095241205041550

Adel Khalifa Sultan Hamad, Jassim Haji

{"title":"Artificial Intelligence in the Heart of Medicine: Transforming Arrhythmia Care with Intelligent Systems.","authors":"Adel Khalifa Sultan Hamad, Jassim Haji","doi":"10.2174/011573403X334095241205041550","DOIUrl":"https://doi.org/10.2174/011573403X334095241205041550","url":null,"abstract":"Background: At a critical juncture in the ongoing fight against cardiovascular disease (CVD), healthcare professionals are striving for more informed and expedited decisionmaking. Artificial Intelligence (AI) promises to be a guiding light in this endeavor. The diagnosis of coronary artery disease has now become non-invasive and convenient, while wearable devices excel at promptly detecting life-threatening arrhythmias and treatments for heart failure.Objective: This study aimed to highlight the applications of AI in cardiology with a particular focus on arrhythmias and its potential impact on healthcare for all through careful implementation and constant research efforts.Methods: An extensive search strategy was implemented. The search was conducted in renowned electronic medical databases, including Medline, PubMed, Cochrane Library, and Google Scholar. Artificial Intelligence, cardiovascular diseases, arrhythmias, machine learning, and convolutional neural networks in cardiology were used as keywords for the search strategy.Results: A total of 6876 records were retrieved from different electronic databases. Duplicates (N = 1356) were removed, resulting in 5520 records for screening. Based on predefined inclusion and exclusion criteria, 4683 articles were excluded. Following the full-text screening of the remaining 837 articles, a further 637 were excluded. Ultimately, 200 studies were included in this review.Conclusion: AI represents not just a development but a cutting-edge force propelling the next evolution of cardiology. With its capacity to make precise predictions, facilitate non-invasive diagnosis, and personalize therapies, AI holds the potential to save lives and enhance healthcare quality on a global scale.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review.

IF 2.4

Current Cardiology Reviews Pub Date : 2025-01-31 DOI: 10.2174/011573403X334668241227074314

Maryam Kayani, Gadde Krishna Sangeetha, Swapna Sarangi, Leela Sarmada G, Shelja Sharma, Victor O Adedara, Saria Abdallah, Kristina Katz, Glendalys Rodríguez Mora, Sravani Kommuru, Zahra Nazir

{"title":"Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review.","authors":"Maryam Kayani, Gadde Krishna Sangeetha, Swapna Sarangi, Leela Sarmada G, Shelja Sharma, Victor O Adedara, Saria Abdallah, Kristina Katz, Glendalys Rodríguez Mora, Sravani Kommuru, Zahra Nazir","doi":"10.2174/011573403X334668241227074314","DOIUrl":"https://doi.org/10.2174/011573403X334668241227074314","url":null,"abstract":"Pharmacogenomics has transformed the way we approach the treatment of the most common diseases worldwide, especially cardiovascular. In this article, we highlight the main categories of drugs involved in major cardiovascular diseases (CVD), related genetic variability and their effects on metabolism in each case of contrastive operability. This not only explains disparities in treatment outcomes but also unfolds customised management based on genomic studies to improve efficiency and limit side effects. Genetic variations have been identified that impact the efficacy, safety, and adverse effects of drugs commonly used in the treatment of CVDs, such as Angiotensin converting Enzyme Inhibitor (ACEI), Angiotensin Receptor Blocker (ARBs), calcium channel blockers, antiplatelet agents, diuretics, statins, beta-blockers, and anticoagulants. It discusses the impact of genetic polymorphisms on drug metabolism, efficacy, and adverse reactions, highlighting the importance of genetic testing in optimizing treatment outcomes. Pharmacogenomics holds immense potential for revolutionizing the management of CVDs by enabling personalized medicine approaches tailored to individual genetic profiles. However, challenges such as clinical implementation, cost-effectiveness, and ethical considerations need to be addressed to completely incorporate pharmacogenomic testing into standard clinical practice. Continued research and clinical diligence are required for the utilization of pharmacogenomics to improve therapeutic outcomes and reduce the burden of CVD globally.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0